Co-founder and COO Dr. Jan Pietas attended the conference and presented the poster “Decoding the Human Heart”, which provided a structured overview of the myotwin platform and its application in preclinical drug development. The subsequent discussions led to an intensive scientific exchange with experts from various areas of drug discovery. Feedback regarding the value of human-based models once again underscored the importance of the myotwin approach for early-stage research.
Overall, myotwin considers its first participation in ELRIG Drug Discovery a success. The event offered opportunities for scientific interaction, highlighted potential starting points for collaborations, and provided valuable impulses for the next steps.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary TrinityScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
